BMS< Opdivo

Showing 1 posts of 1 posts found.

BMS’ Opdivo fails to improve overall survival in small-cell lung cancer

October 15, 2018
Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …

Latest content